Sentinel Lymph Node Biopsy
On this page
Direct answer
The sentinel node is the first lymph node receiving drainage from a tumour, and mapping it lets the surgeon stage the whole basin by removing one or two nodes instead of fifteen. Dual-tracer identification — radioisotope plus blue dye — succeeds in over 95 per cent of axillas with a false-negative rate near 5 per cent when technique is disciplined. The technique's recent contribution has been subtractive rather than additive: Z0011 and AMAROS in breast cancer and MSLT-II in melanoma have abolished the automatic completion dissection that once followed a positive sentinel node. Tracer choice, node counts and the response to a positive result all shift with tumour type, treatment sequence and pregnancy.
What you must remember
- Tracers: Tc-99m-labelled colloid or tilmanocept, blue dye (isosulfan blue; methylene blue is widely used in India on cost grounds), and indocyanine green with near-infrared imaging.
- Pregnancy: blue dye is avoided; radioisotope mapping alone is acceptable because fetal dose is negligible. Isosulfan blue carries roughly 1 per cent anaphylaxis risk.
- Nodal burden language: isolated tumour cells ≤0.2 mm, micrometastases >0.2–2 mm, macrometastases >2 mm — management differs at each threshold.
- ACOSOG Z0011: one to two positive sentinel nodes, T1–2 cN0, breast conservation with whole-breast radiotherapy, no neoadjuvant chemotherapy — axillary dissection may be omitted.
- AMAROS: axillary radiotherapy equals dissection for a positive sentinel node with less lymphoedema; IBCSG 23-01 showed dissection adds nothing for micrometastases.
- Melanoma: offer sentinel biopsy above 0.8 mm thickness or for any ulcerated thin tumour; MSLT-II and DeCOG support ultrasound surveillance over completion dissection when the node is positive.
- After neoadjuvant chemotherapy converting cN1 to cN0, the pre-chemotherapy clipped node must be excised with dual tracer and at least three nodes harvested (Z1071, SENTINA), or the false-negative rate climbs steeply.
- Lymphoedema: 15–30 per cent after axillary dissection versus under 10 per cent after sentinel biopsy — the strongest argument for staging before cutting.
Working through a positive sentinel node
A 48-year-old woman with a 2.5 cm ER-positive carcinoma, clinically node-negative, undergoes wide local excision with dual-tracer sentinel biopsy; one of two nodes carries a 4 mm metastasis. Every Z0011 condition is met — breast conservation, no neoadjuvant, one positive node — so no axillary dissection is done; whole-breast radiotherapy plus endocrine therapy covers the basin. Now change one variable: she chooses mastectomy. The Z0011 evidence evaporates because there is no whole-breast radiotherapy to sterilise residual axillary disease; the options become completion dissection or axillary radiotherapy on AMAROS grounds. Change a second variable: she presented cN1, received neoadjuvant chemotherapy and converted — sentinel biopsy is still permissible, but only with the clipped node retrieved and three or more nodes sampled. The technique is constant; the evidence moves with each line of the vignette, which is precisely how the examination asks it.
How the exam frames it
Questions rarely ask what a sentinel node is; they quote a trial and test whether you know its boundary conditions. The recurring traps are Z0011 applied to mastectomy or post-neoadjuvant patients (both excluded from the trial), a 0.2 mm focus labelled micrometastasis when it is isolated tumour cells, and methylene blue causing a spurious low pulse-oximetry reading — a favourite image-based distractor. A classic viva sequence is breast cancer in pregnancy: which tracer is safe, and the expected answer is radioisotope alone, blue dye withheld.
Frequently asked questions
Which tracer is used for sentinel node biopsy in pregnancy?
Radioisotope alone is considered acceptable because fetal radiation dose is negligible; blue dyes are avoided because of anaphylaxis risk and fetal concerns.
What did ACOSOG Z0011 establish?
In cN0 T1–2 breast cancer treated with conservation and whole-breast radiotherapy, omitting axillary dissection for one or two positive sentinel nodes did not worsen survival or regional control.
When does a positive sentinel node still require axillary dissection?
After mastectomy without planned radiotherapy, with three or more involved sentinel nodes, gross residual nodal disease, or when Z0011 criteria such as no-neoadjuvant treatment are not met.
How is sentinel biopsy performed after neoadjuvant chemotherapy?
Clip the biopsy-proven node before chemotherapy; at surgery use dual tracer, retrieve the clipped node and at least three nodes total — the safeguards that keep the false-negative rate acceptable.
What size defines a micrometastasis?
Greater than 0.2 mm up to 2 mm; deposits of 0.2 mm or less are isolated tumour cells, and deposits beyond 2 mm are macrometastases.
What is the role of sentinel node biopsy outside breast cancer?
In melanoma it is offered above 0.8 mm thickness or with ulceration, and in endometrial cancer indocyanine-green mapping (FIRES trial) has become a staging alternative to systematic lymphadenectomy.